HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Role of nitric oxide in the vasodilator effect of recombinant human growth hormone in patients with dilated cardiomyopathy.

AbstractOBJECTIVE:
Dilated cardiomyopathy is characterized by elevated arterial vascular resistance and impaired nitric oxide (NO)-dependent vasodilation. Insulin-like growth factor-I (IGF-I) has been shown to stimulate endothelial NO-synthase resulting in endothelium-dependent vasodilation. Growth hormone (GH) substitution therapy leads in GH-deficient patients to significant increases of IGF-I which may alter systemic vascular resistance by stimulating NO production. This study was designed to evaluate the effects of treatment with recombinant human growth hormone (GH) on NO production and NO-dependent vascular effects in patients with dilated cardiomyopathy.
METHODS:
50 patients with dilated cardiomyopathy were randomly assigned to double-blind treatment with 2 I.U. of GH or placebo for 3 months. Central hemodynamics were determined by Swan-Ganz catheter and cardiac output was obtained by the thermodilution method. Serum GH and IGF-I levels were measured and systemic NO production was determined from urinary nitrate and cyclic GMP excretion rates in 42 patients.
RESULTS:
GH treatment caused in comparison to the placebo group a significant increase of IGF-I by 91 ng/ml (P = 0.0001). Urinary excretion rates of nitrate and cyclic GMP increased also significantly by 38 mumol/mmol creatinine (P = 0.027) and 65 nmol/mmol creatinine (P = 0.003), respectively. The parallel increase of both marker molecules indicates increased systemic NO production during GH treatment.
CONCLUSION:
GH treatment induces a significant, but moderate increase of systemic NO production in patients with dilated cardiomyopathy. This effect may be mediated by IGF-I stimulating endothelial NO synthase.
AuthorsK J Osterziel, S M Bode-Böger, O Strohm, A E Ellmer, N Bit-Avragim, D Hänlein, M B Ranke, R Dietz, R H Böger
JournalCardiovascular research (Cardiovasc Res) Vol. 45 Issue 2 Pg. 447-53 (Jan 14 2000) ISSN: 0008-6363 [Print] England
PMID10728365 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Nitrates
  • Nitric Oxide
  • Insulin-Like Growth Factor I
  • Growth Hormone
  • Cyclic GMP
Topics
  • Cardiomyopathy, Dilated (drug therapy, metabolism)
  • Chi-Square Distribution
  • Cyclic GMP (urine)
  • Double-Blind Method
  • Female
  • Growth Hormone (blood, therapeutic use)
  • Humans
  • Insulin-Like Growth Factor I (analysis)
  • Male
  • Middle Aged
  • Nitrates (urine)
  • Nitric Oxide (physiology)
  • Regression Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: